diethylnitrosamine has been researched along with leflunomide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamed, O; Kazem, A; Nasr, M; Selima, E | 1 |
| Abass, SA; Abdel-Hamid, NM; Abdel-Kareem, MA; Eldomany, RA; Zakaria, S | 1 |
2 other study(ies) available for diethylnitrosamine and leflunomide
| Article | Year |
|---|---|
Targeting different angiogenic pathways with combination of curcumin, leflunomide and perindopril inhibits diethylnitrosamine-induced hepatocellular carcinoma in mice.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Antirheumatic Agents; Carcinogens; Carcinoma, Hepatocellular; Curcumin; Diethylnitrosamine; Drug Therapy, Combination; Hypoxia-Inducible Factor 1, alpha Subunit; Isoxazoles; Leflunomide; Liver; Liver Neoplasms; Male; Mice; Neovascularization, Pathologic; Perindopril; Platelet Endothelial Cell Adhesion Molecule-1; Vascular Endothelial Growth Factor A | 2014 |
Dual regulating of mitochondrial fusion and Timp-3 by leflunomide and diallyl disulfide combination suppresses diethylnitrosamine-induced hepatocellular tumorigenesis in rats.
Topics: Alkylating Agents; Allyl Compounds; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disulfides; Drug Therapy, Combination; Gene Expression Regulation, Neoplastic; Immunosuppressive Agents; Leflunomide; Liver Neoplasms, Experimental; Male; Mitochondrial Dynamics; Rats; Rats, Wistar; Tissue Inhibitor of Metalloproteinase-3 | 2022 |